INT41152

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.12
First Reported 1983
Last Reported 1995
Negated 0
Speculated 0
Reported most in Abstract
Documents 3
Total Number 4
Disease Relevance 0.11
Pain Relevance 2.91

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Slc3a1) extracellular region (Penk) plasma membrane (Slc3a1)
carbohydrate metabolic process (Slc3a1)
Anatomy Link Frequency
hippocampal formation 1
medial 1
neurons 1
Penk (Rattus norvegicus)
Slc3a1 (Rattus norvegicus)
Slc3a1 - S2L (1)
Pain Link Frequency Relevance Heat
Enkephalin 25 100.00 Very High Very High Very High
agonist 2 99.98 Very High Very High Very High
opioid receptor 6 99.82 Very High Very High Very High
Nucleus accumbens 1 95.24 Very High Very High Very High
narcan 1 93.12 High High
amygdala 2 92.92 High High
MU agonist 4 91.36 High High
cerebral cortex 1 86.72 High High
Dynorphin 1 85.44 High High
midbrain 3 84.92 Quite High
Disease Link Frequency Relevance Heat
Nociception 2 54.08 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Since D2 receptor mRNA is generally colocalized with proenkephalin mRNA in striatal neurons, these results demonstrate what is likely a selective cellular increase in proenkephalin mRNA without a parallel increase in D2 mRNA.
proenkephalin Binding (colocalized) of D2 in neurons
1) Confidence 0.12 Published 1994 Journal Exp. Neurol. Section Abstract Doc Link 7867758 Disease Relevance 0 Pain Relevance 0.30
At 0.5 microgram and 1 microgram intracerebroventricularly the highly selective mu-opioid receptor agonist D-Ala2, MePhe4, Gly-ol5-enkephalin effected statistically significant increases as well as statistically significant decreases in regional glucose utilization: in limbic structures, such as hippocampal formation, medial amygdala and lateral septum, glucose utilization was most prominently increased after D-Ala2, MePhe4, Gly-ol5-enkephalin; glucose utilization was further increased in the lateral habenular nucleus, the hypothalamus, ventromedial nucleus and dorsal raphe; whereas decreases were found in the mamillary body and anterior thalamus.
Gly-ol5-enkephalin Binding (effected) of D-Ala2 in hippocampal formation associated with agonist, thalamus, enkephalin, opioid receptor, raphe and amygdala
2) Confidence 0.01 Published 1995 Journal Brain Res. Section Abstract Doc Link 8593578 Disease Relevance 0.05 Pain Relevance 0.55
A modified enkephalin ([D-Ser2]Leu-enkephalin-Thr) with selective affinity for the delta subclass of enkephalin receptor was effective in inhibiting proline uptake.
enkephalin receptor Binding (affinity) of D-Ser2 (S2L) associated with enkephalin
3) Confidence 0.01 Published 1983 Journal J. Biol. Chem. Section Abstract Doc Link 6138350 Disease Relevance 0 Pain Relevance 1.52
At 0.5 microgram and 1 microgram intracerebroventricularly the highly selective mu-opioid receptor agonist D-Ala2, MePhe4, Gly-ol5-enkephalin effected statistically significant increases as well as statistically significant decreases in regional glucose utilization: in limbic structures, such as hippocampal formation, medial amygdala and lateral septum, glucose utilization was most prominently increased after D-Ala2, MePhe4, Gly-ol5-enkephalin; glucose utilization was further increased in the lateral habenular nucleus, the hypothalamus, ventromedial nucleus and dorsal raphe; whereas decreases were found in the mamillary body and anterior thalamus.
Gly-ol5-enkephalin Binding (effected) of D-Ala2 in medial associated with agonist, thalamus, enkephalin, opioid receptor, raphe and amygdala
4) Confidence 0.00 Published 1995 Journal Brain Res. Section Abstract Doc Link 8593578 Disease Relevance 0.05 Pain Relevance 0.55

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox